Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 14/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | EBP | Q15125 | 1/20 | 0.36 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL492916 | 0.93 | BDKRB1 (0.40) | EPHX2LMNASMN1; SMN2PKMKMT2A | |
| SCHEMBL492906 | 0.92 | EPHX2 (0.47) | EPHX2EBPDHCR7KMT2AMEN1 | |
| SCHEMBL493908 | 0.92 | EPHX2 (0.41) | EPHX2PKMEBPDHCR7 | |
| SCHEMBL493338 | 0.90 | EPHX2 (0.40) | EPHX2LMNASMN1; SMN2PKMKMT2A | |
| SCHEMBL493775 | 0.89 | EPHX2 (0.42) | EPHX2LMNAKMT2A | |
| SCHEMBL492924 | 0.89 | PKM (0.47) | EPHX2LMNASMN1; SMN2PKMKMT2A | |
| SCHEMBL493342 | 0.89 | PKM (0.48) | EPHX2LMNASMN1; SMN2PKMKMT2A | |
| SCHEMBL492606 | 0.88 | EPHX2 (0.41) | EPHX2LMNAKMT2A | |
| SCHEMBL493187 | 0.87 | PKM (0.44) | EPHX2PKMKMT2AMEN1L3MBTL1 | |
| SCHEMBL493278 | 0.86 | SMN1; SMN2 (0.38) | EPHX2LMNASMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | EPHX2 2567/4885LMNA 2485/4885SMN1; SMN2 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.